The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.

abstract：:Advanced and metastatic squamous cell carcinomas (SCC) are common and difficult-to-treat malignancies. We assessed 75 immunotherapy-treated patients with SCC from a clinically annotated database of 2,651 patients, as well as 9,407 patients from a deidentified database for molecular features that might influence checkp...

journal_title：Cancer immunology research

authors： Goodman AM,Kato S,Chattopadhyay R,Okamura R,Saunders IM,Montesion M,Frampton GM,Miller VA,Daniels GA,Kurzrock R

更新日期：2019-06-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a B-cell neoplasia characterized by protumor immune dysregulation involving nonmalignant cells of the microenvironment, including T lymphocytes and tumor-associated myeloid cells. Although therapeutic agents have improved treatment options for CLL, many patients still fail to resp...

journal_title：Cancer immunology research

authors： Banerjee P,Zhang R,Ivan C,Galletti G,Clise-Dwyer K,Barbaglio F,Scarfò L,Aracil M,Klein C,Wierda W,Plunkett W,Caligaris-Cappio F,Gandhi V,Keating MJ,Bertilaccio MTS

更新日期：2019-12-01 00:00:00

abstract：:Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

journal_title：Cancer immunology research

authors： Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

更新日期：2018-03-01 00:00:00

abstract：:Macroenvironmental factors, including a patient's physical and social environment, play a role in cancer risk and progression. Our previous studies show that living in an enriched environment (EE) providing complex stimuli confers an anticancer phenotype in mice mediated, in part by a specific neuroendocrine axis, wit...

journal_title：Cancer immunology research

authors： Xiao R,Bergin SM,Huang W,Slater AM,Liu X,Judd RT,Lin ED,Widstrom KJ,Scoville SD,Yu J,Caligiuri MA,Cao L

更新日期：2016-06-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of cancers of hematopoietic origin. In the immunosuppressive solid tumor environment, CAR T cells encounter obstacles that compromise their efficacy. We developed a strategy to address these barriers by having CAR T cells secrete single-domai...

journal_title：Cancer immunology research

authors： Xie YJ,Dougan M,Ingram JR,Pishesha N,Fang T,Momin N,Ploegh HL

更新日期：2020-04-01 00:00:00

abstract：:The FDA-AACR Oncology Dose-Finding Workshop, Part 3, was held in Washington, DC, on July 20, 2017, as a continuation of the previous two collaborative dose-finding and optimization workshops presented by the FDA and AACR. This year's workshop focused on combination therapy with immune-oncology agents and best practice...

journal_title：Cancer immunology research

authors： Emens LA,Bruno R,Rubin EH,Jaffee EM,McKee AE

更新日期：2017-12-01 00:00:00

abstract：:The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, I...

journal_title：Cancer immunology research

authors： Charbonneau B,Moysich KB,Kalli KR,Oberg AL,Vierkant RA,Fogarty ZC,Block MS,Maurer MJ,Goergen KM,Fridley BL,Cunningham JM,Rider DN,Preston C,Hartmann LC,Lawrenson K,Wang C,Tyrer J,Song H,deFazio A,Johnatty SE,Doher

更新日期：2014-04-01 00:00:00

abstract：:In the past five decades, the role for lymphocytes in host immune response to tumors has been shown, at least in some patients, to be a critical component in disease prognosis. Also, the heterogeneity of lymphocytes has been documented, including the existence of regulatory T cells that suppress the immune response. A...

journal_title：Cancer immunology research

authors： Mihm MC Jr,Mulé JJ

更新日期：2015-08-01 00:00:00

abstract：:Freeze-dried black raspberries (BRB), their component anthocyanins (AC), and a metabolite of BRB ACs, protocatechuic acid (PCA), inhibit the development of esophageal cancer in rats induced by the carcinogen, N-nitrosomethylbenzylamine (NMBA). All three components reduce inflammation in the esophagus and in plasma. Th...

journal_title：Cancer immunology research

authors： Peiffer DS,Wang LS,Zimmerman NP,Ransom BW,Carmella SG,Kuo CT,Chen JH,Oshima K,Huang YW,Hecht SS,Stoner GD

更新日期：2016-01-01 00:00:00

abstract：:Caspase recuitment domain-containing protein 9 (CARD9) functions in different inflammation pathways to elicit responses to microbial signals and is known to affect intestinal inflammation. Examining the APC(min) mouse model of intestinal tumorigenesis and using stringently controlled, sex- and age-matched pairs of CAR...

journal_title：Cancer immunology research

authors： Leo VI,Tan SH,Bergmann H,Cheah PY,Chew MH,Lim KH,Ruland J,Reilly PT

更新日期：2015-07-01 00:00:00

abstract：:Granulocytic-macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients wi...

journal_title：Cancer immunology research

authors： Wei XX,Chan S,Kwek S,Lewis J,Dao V,Zhang L,Cooperberg MR,Ryan CJ,Lin AM,Friedlander TW,Rini B,Kane C,Simko JP,Carroll PR,Small EJ,Fong L

更新日期：2016-11-01 00:00:00

abstract：:Individuals of African descent are disproportionately affected by specific complex diseases, such as breast and prostate cancer, which are driven by both biological and nonbiological factors. In the case of breast cancer, there is clear evidence that psychosocial factors (environment, socioeconomic status, health beha...

journal_title：Cancer immunology research

authors： Yeyeodu ST,Kidd LR,Kimbro KS

更新日期：2019-09-01 00:00:00

abstract：:Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, a...

journal_title：Cancer immunology research

authors： Kim HJ,Cantor H

更新日期：2014-10-01 00:00:00

abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

journal_title：Cancer immunology research

authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

更新日期：2018-06-01 00:00:00

abstract：:Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that the presence of somatic mutations is associated with benefit from checkpoint inhibition. A hypothesis...

journal_title：Cancer immunology research

authors： Nathanson T,Ahuja A,Rubinsteyn A,Aksoy BA,Hellmann MD,Miao D,Van Allen E,Merghoub T,Wolchok JD,Snyder A,Hammerbacher J

更新日期：2017-01-01 00:00:00

abstract：:The presence and activity of CD8+ T cells within the tumor microenvironment are essential for the control of tumor growth. Utilizing B16-F10 melanoma tumors that express altered peptide ligands of chicken ovalbumin, OVA257-264, we measured high- and low-affinity OVA-specific responses following adoptive transfer of OT...

journal_title：Cancer immunology research

authors： Snook JP,Soedel AJ,Ekiz HA,O'Connell RM,Williams MA

更新日期：2020-04-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. Pancreatic tumors are minimally infiltrated by T cells and are largely refractory to immunotherapy. Accordingly, the role of T-cell immunity in pancreatic cancer has been somewhat overlooked. Here, we hypothesized ...

journal_title：Cancer immunology research

authors： Ajina R,Malchiodi ZX,Fitzgerald AA,Zuo A,Wang S,Moussa M,Cooper CJ,Shen Y,Johnson QR,Parks JM,Smith JC,Catalfamo M,Fertig EJ,Jablonski SA,Weiner LM

更新日期：2021-01-28 00:00:00

abstract：:On September 25-28, 2016, in New York City, the Second International Cancer Immunotherapy Conference was cohosted by the Cancer Research Institute, the American Association for Cancer Research, the Association for Cancer Immunotherapy, and the European Academy of Tumor Immunology. This exciting conference brought toge...

journal_title：Cancer immunology research

authors： Brodsky AN,Hubbard-Lucey VM

更新日期：2016-12-01 00:00:00

abstract：:Immunotherapy with monoclonal antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) has improved the survival of patients with metastatic melanoma. These agents carry a certain risk of adverse immune-related events. We present a patient with widely metastatic melanoma who was...

journal_title：Cancer immunology research

authors： Maurice C,Schneider R,Kiehl TR,Bavi P,Roehrl MH,Mason WP,Hogg D

更新日期：2015-12-01 00:00:00

abstract：:Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

journal_title：Cancer immunology research

authors： Hansmann L,Han A,Penter L,Liedtke M,Davis MM

更新日期：2017-09-01 00:00:00

abstract：:Immunotherapies targeting T lymphocytes are revolutionizing cancer therapy but only benefit a subset of patients, especially in colorectal cancer. Thus, additional insight into the tumor microenvironment (TME) is required. Eosinophils are bone marrow-derived cells that have been largely studied in the context of aller...

journal_title：Cancer immunology research

authors： Reichman H,Itan M,Rozenberg P,Yarmolovski T,Brazowski E,Varol C,Gluck N,Shapira S,Arber N,Qimron U,Karo-Atar D,Lee JJ,Munitz A

更新日期：2019-03-01 00:00:00

abstract：:New immunotherapeutic strategies are needed to induce effective antitumor immunity in all cancer patients. Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies. Infiltration of tumor-associated macrophages (TAM) is prominent in mesothelioma and is linked to immune suppre...

journal_title：Cancer immunology research

authors： Dammeijer F,Lievense LA,Kaijen-Lambers ME,van Nimwegen M,Bezemer K,Hegmans JP,van Hall T,Hendriks RW,Aerts JG

更新日期：2017-07-01 00:00:00

abstract：:Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microenvironment (TME) should also attract and activate immune effectors wit...

journal_title：Cancer immunology research

authors： Parihar R,Rivas C,Huynh M,Omer B,Lapteva N,Metelitsa LS,Gottschalk SM,Rooney CM

更新日期：2019-03-01 00:00:00

abstract：:Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention o...

journal_title：Cancer immunology research

authors： Vandeven N,Nghiem P

更新日期：2014-01-01 00:00:00

abstract：:With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB geneti...

journal_title：Cancer immunology research

authors： DeVette CI,Andreatta M,Bardet W,Cate SJ,Jurtz VI,Jackson KW,Welm AL,Nielsen M,Hildebrand WH

更新日期：2018-06-01 00:00:00

abstract：:Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could ...

journal_title：Cancer immunology research

authors： Müller P,Martin K,Theurich S,Schreiner J,Savic S,Terszowski G,Lardinois D,Heinzelmann-Schwarz VA,Schlaak M,Kvasnicka HM,Spagnoli G,Dirnhofer S,Speiser DE,von Bergwelt-Baildon M,Zippelius A

更新日期：2014-08-01 00:00:00

abstract：:Ipilimumab, a novel immune checkpoint inhibitor, is associated with long-term survival in approximately 20% of patients with advanced melanoma and is also being evaluated in the adjuvant setting. With this growing cohort of survivors, long-term health outcomes, chronic toxicities, and functional outcomes among survivo...

journal_title：Cancer immunology research

authors： Johnson DB,Friedman DL,Berry E,Decker I,Ye F,Zhao S,Morgans AK,Puzanov I,Sosman JA,Lovly CM

更新日期：2015-05-01 00:00:00

abstract：:Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

journal_title：Cancer immunology research

authors： Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

更新日期：2014-09-01 00:00:00

abstract：:Preventive vaccination against tumor-associated endogenous antigens is considered to be an attractive strategy for the induction of a curative immune response concomitant with a long-lasting immunologic memory. The mucin MUC1 is a promising tumor antigen, as its tumor-associated form differs from the glycoprotein form...

journal_title：Cancer immunology research

authors： Stergiou N,Gaidzik N,Heimes AS,Dietzen S,Besenius P,Jäkel J,Brenner W,Schmidt M,Kunz H,Schmitt E

更新日期：2019-01-01 00:00:00

abstract：:The current standard of care for treatment of metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes for 19 mRCC patients who experienced an initial clinical response (any degree of tumor shrinkage), but after immune-related a...

journal_title：Cancer immunology research

authors： Martini DJ,Hamieh L,McKay RR,Harshman LC,Brandao R,Norton CK,Steinharter JA,Krajewski KM,Gao X,Schutz FA,McGregor B,Bossé D,Lalani AA,De Velasco G,Michaelson MD,McDermott DF,Choueiri TK

更新日期：2018-04-01 00:00:00